Tags

Type your tag names separated by a space and hit enter

Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
Am J Cardiol. 2007 Dec 17; 100(12A):27P-32P.AJ

Abstract

Rimonabant is the first selective blocker of the cannabinoid-1 receptor in development for the treatment of obesity, diabetes mellitus, and cardiometabolic risk factors. (Recently, an FDA Advisory Committee recommended a delay in the approval of rimonabant because of safety issues that need to be addressed in further studies.) Although it is associated with favorable effects on weight, waist circumference, serum lipids, C-reactive protein, and an improvement in glycemic control in type 2 diabetes, there are concerns about side effects. Generally, rimonabant has been well tolerated, with a primary side effect of nausea. Other side effects seen in trials have been anxiety and depressive symptoms, as well as neurologic events, albeit at low rates. When rimonabant becomes clinically available, physicians should be vigilant regarding the expected side effects and use alternative therapies if needed.

Authors+Show Affiliations

Department of Medicine, Johns Hopkins Hospital, Baltimore, Maryland, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18154743

Citation

Steinberg, Benjamin A., and Christopher P. Cannon. "Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Safety, Tolerability, and Therapeutic Potential." The American Journal of Cardiology, vol. 100, no. 12A, 2007, 27P-32P.
Steinberg BA, Cannon CP. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. Am J Cardiol. 2007;100(12A):27P-32P.
Steinberg, B. A., & Cannon, C. P. (2007). Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. The American Journal of Cardiology, 100(12A), 27P-32P.
Steinberg BA, Cannon CP. Cannabinoid-1 Receptor Blockade in Cardiometabolic Risk Reduction: Safety, Tolerability, and Therapeutic Potential. Am J Cardiol. 2007 Dec 17;100(12A):27P-32P. PubMed PMID: 18154743.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. AU - Steinberg,Benjamin A, AU - Cannon,Christopher P, PY - 2007/12/25/pubmed PY - 2008/2/6/medline PY - 2007/12/25/entrez SP - 27P EP - 32P JF - The American journal of cardiology JO - Am J Cardiol VL - 100 IS - 12A N2 - Rimonabant is the first selective blocker of the cannabinoid-1 receptor in development for the treatment of obesity, diabetes mellitus, and cardiometabolic risk factors. (Recently, an FDA Advisory Committee recommended a delay in the approval of rimonabant because of safety issues that need to be addressed in further studies.) Although it is associated with favorable effects on weight, waist circumference, serum lipids, C-reactive protein, and an improvement in glycemic control in type 2 diabetes, there are concerns about side effects. Generally, rimonabant has been well tolerated, with a primary side effect of nausea. Other side effects seen in trials have been anxiety and depressive symptoms, as well as neurologic events, albeit at low rates. When rimonabant becomes clinically available, physicians should be vigilant regarding the expected side effects and use alternative therapies if needed. SN - 0002-9149 UR - https://www.unboundmedicine.com/medline/citation/18154743/Cannabinoid_1_receptor_blockade_in_cardiometabolic_risk_reduction:_safety_tolerability_and_therapeutic_potential_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(07)02070-X DB - PRIME DP - Unbound Medicine ER -